Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR

Journal of Infectious Diseases

Volumn 182, Issue 4, 2000, Pages 1199-1206

  Cooper, Philip J ^a   Chico, Martha E ^d   Losonsky, Genevieve ^b   Sandoval, Carlos ^d   Espinel, Ivan ^d   Sridhara, Rajeshwari ^c   Aguilar, Marcelo ^e   Guevara, Angel ^d   Guderian, Ronald H ^d   Levine, Myron M ^b   Griffin, George E ^f   Nutman, Thomas B ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c EMMES CORPORATION   (United States)

^d HOSPITAL VOZANDES   (Ecuador)

^e Ministry of Public Health   (Ecuador)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; CHOLERA VACCINE; LIVE VACCINE; PLACEBO;

ANTIBODY RESPONSE; ARTICLE; ASCARIASIS; ASCARIS LUMBRICOIDES; BLOOD GROUP; CHILD; CHILDHOOD DISEASE; CHOLERA; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

ADOLESCENT; ALBENDAZOLE; ANIMALS; ANTHELMINTICS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ASCARIASIS; ASCARIS LUMBRICOIDES; BACTERIAL VACCINES; BLOOD GROUP ANTIGENS; CHILD; CHOLERA VACCINES; DRUG INTERACTIONS; ECUADOR; FEMALE; HUMANS; MALE; TRICHURIS; VACCINES, ATTENUATED;

EID: 0033805081     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315837     Document Type: Article

References (49)

1. Ascariasis and human nutrition
2. Geohelminth infection and academic assessment in Jamaican children
3. Ascariasis and childhood malnutrition
4. Malabsorption syndrome in ascariasis
5. Soil-transmitted helminths (geohelminths)
6. The global burden of intestinal nematode infections: Fifty years on
7. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference
8. Factors affecting immunogenicity of oral poliovirus vaccine in developing countries: Review
9. Outbreak of paralytic poliomyelitis in Oman: Evidence for widespread transmission among fully vaccinated children
10. Safety, immunogenicity and efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru
11. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil
12. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand
13. Safety and immunogenicity of single-dose live oral choler vaccine CVD 103-HgR in 5-9-year-old Indonesian children
14. Outbreak of paralytic poliomyelitis in Namibia
15. Safety, immunogenicity and efficacy in man of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR
16. Randomized double-blind placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103 HgR in Swiss adults
17. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103 HgR: Results of a randomized, placebo-controlled, double-blind cross-over trial
18. Safety, immunogenicity, and excretion pattern of single-dose rive oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic status
19. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR
20. Biopsy of small bowel of Thai people
21. Microbial contamination of the gut: Another feature of malnutrition
22. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni
23. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: A possible role for interleukin-10
24. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults
25. Rapid onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR
26. Anthelmintics: A comparative review of their clinical pharmacology
27. Serological studies on cholera. II. The vibriocidal antibody response of cholera patients determined by a microtechnique
28. ABO blood groups and cholera
29. Genetic susceptibility to cholera
30. Seroepidemiological studies of El Tor cholera in Bangladesh: Association of serum antibody levels and protection
31. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O
32. Kinetics of the vibriocidal antibody response to live oral cholera vaccine
33. Field trial of oral cholera vaccines in Bangladesh: Serum vibriocidal and antitoxic antibodies as markers of the risk of cholera
34. Immunity and vaccine development
35. Comparative prevalences of Ascaris lumbricoides, Trichuris trichiura and hookworm infections and the prospects for combined control
36. Randomized trial of albendazole and pyrantel in symptomless trichuriasis in children
37. Immunoepidemiology of intestinal helminthic infections. I. The global burden of intestinal nematode disease
38. Microsporidiosis
39. Albendazole and infections with Trichuris trichiura and Giardia intestinalis
40. ABH and related histo-blood group antigens: Immunochemical differences in carrier isotypes and their distribution
41. Blood group antigens as tumor markers, parasitic/bacterial/viral receptors, and their association with immunologically important proteins
42. Lewis histo-blood group system and associated secretory phenotypes
43. Possible role of blood-group secretory substances in the aetiology of cholera
44. Cholera toxin stimulates secretion of immunoreactive intestinal mucin
45. Cholera enterotoxin-induced mucus secretion and increase in the mucus blanket of the rabbit ileum in vivo
46. Targeted anthelminthic treatment of school children: Effect of frequency of application on the intensity of Ascaris lumbricoides infection in children from rural Nigerian villages
47. The children's vaccine initiative